AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25177431 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of steroid and Korean red ginseng (KRG)
Number of subjects: 73
Study 25177431 — intervention group
Group type: COMPARATOR
Intervention: Steroid therapy alone
Number of subjects: 73
Study 25177431 — intervention group
Group type: EXPERIMENTAL
Intervention: KRG as an adjuvant to steroid therapy
Number of subjects: 73
Study 21763393 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 369
Study 21763393 — intervention group
Group type: COMPARATOR
Intervention: Bag-Mask Ventilation (BMV)
Number of subjects: 369
Study 19523608 — intervention group
Group type: EXPERIMENTAL
Intervention: Live oral cholera vaccine VA1.3 (5 x 10(9) CFU)
Number of subjects: 304
Study 19523608 — intervention group
Group type: COMPARATOR
Intervention: Placebo (diluent buffer)
Number of subjects: 304
Study 17530295 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus acidophilus 10(8) CFU/g 1 g b.i.d.)
Number of subjects: 120
Study 17530295 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics (trimethoprim/sulfamethoxazole 2/10 mg/kg h.s.)
Number of subjects: 120
Study 15026612 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of aspirin
Number of subjects: 60
Study 15026612 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of aspirin
Number of subjects: 60
Study 15026612 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg of aspirin
Number of subjects: 60
Study 15026612 — intervention group
Group type: EXPERIMENTAL
Intervention: 325 mg of aspirin
Number of subjects: 60
Study 15026612 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of aspirin (AIS subgroup)
Number of subjects: 60
Study 11576461 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha (5 MU/m2 body surface subcutaneously three times per week)
Number of subjects: 44
Study 11576461 — intervention group
Group type: COMPARATOR
Intervention: Control group (CAH B, not treated with IFN-alpha)
Number of subjects: 44
Study 9521254 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrine (80, 120, or 160 mg/day)
Number of subjects: 528
Study 9521254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 528
Study 8005126 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaerobic threshold (AT) determination using various methods (RER, carbon dioxide, minute ventilation, ventilatory equivalents)
Number of subjects: 85
Study 8005126 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossing point method for AT determination
Number of subjects: 85
Study 8005126 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak oxygen uptake assessment
Number of subjects: 85
Study 30829979 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic readiness tests (DRTs)
Number of subjects: 0
Study 30829979 — intervention group
Group type: COMPARATOR
Intervention: Non-ACP clinical placements
Number of subjects: 0
Study 30829979 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment, diagnosis, management, and pharmacology domains
Number of subjects: 0
Study 31618910 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) 5 mg/kg
Number of subjects: 12
Study 31618910 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 12
Study 28556689 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 0
Study 28556689 — intervention group
Group type: COMPARATOR
Intervention: Temsirolimus
Number of subjects: 0
Study 26377150 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic Cochrane Centre information on BCS
Number of subjects: 355
Study 26377150 — intervention group
Group type: COMPARATOR
Intervention: Standard information
Number of subjects: 355
Study 23302821 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure treatment (9-minute daily for 4 weeks)
Number of subjects: 60
Study 23302821 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care (Control group)
Number of subjects: 60
Study 19034054 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined vaginal and oral low‐dose estrogen plus progestogen therapy (EPT)
Number of subjects: 285
Study 19034054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285
Study 17452842 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal melanin spray (Lipoxome) with 3 cycles of 800 nm diode laser at intervals of 8 weeks (28-40 J/cm)
Number of subjects: 16
Study 17452842 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline spray before diode laser treatment
Number of subjects: 16
Study 15050312 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine (500 mg i.v. 20‐30 min before treatment the first 2 days of each week)
Number of subjects: 62
Study 15050312 — intervention group
Group type: COMPARATOR
Intervention: Control group (thoracic RT plus oral etoposide and cisplatin without amifostine)
Number of subjects: 62
Study 11952193 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation treatment
Number of subjects: 163
Study 11952193 — intervention group
Group type: EXPERIMENTAL
Intervention: Patterns of depressive symptoms
Number of subjects: 163
Study 10221371 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital monitor
Number of subjects: 99
Study 10221371 — intervention group
Group type: EXPERIMENTAL
Intervention: Aneroid monitor
Number of subjects: 99
Study 10221371 — intervention group
Group type: COMPARATOR
Intervention: Desktop mercury sphygmomanometer (DMS)
Number of subjects: 99
Study 7529489 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/day finasteride
Number of subjects: 45
Study 7529489 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/day finasteride
Number of subjects: 45
Study 7529489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 2145236 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone (1 mg/kg bolus, every 8 hours for 48 hours)
Number of subjects: 44
Study 2145236 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (frusemide, nitrates, dopamine‐dobutamine)
Number of subjects: 44
Study 438356 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg loperamide HCl (syrup formulation)
Number of subjects: 6
Study 438356 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg loperamide HCl (capsule formulation)
Number of subjects: 6
Study 438356 — intervention group
Group type: COMPARATOR
Intervention: Comparative analysis of syrup and capsule formulations
Number of subjects: 6
Study 438356 — intervention group
Group type: EXPERIMENTAL
Intervention: Excretion of unchanged loperamide
Number of subjects: 6
Study 30267699 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorometholone 0.1% twice daily for 4 weeks
Number of subjects: 154
Study 30267699 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorometholone 0.1% four times daily for 4 weeks
Number of subjects: 154
Study 30267699 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorometholone 0.1% four times daily for 8 weeks
Number of subjects: 154
Study 30267699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 28853994 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole red grape juice (150 ml for men and 100 ml for women)
Number of subjects: 26
Study 28853994 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole red grape juice
Number of subjects: 26
Study 28853994 — intervention group
Group type: COMPARATOR
Intervention: Control drink
Number of subjects: 26
Study 25955226 — intervention group
Group type: EXPERIMENTAL
Intervention: PTH (1-84) 100 μg/d
Number of subjects: 62
Study 25955226 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 23685057 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic plasma exchange (TPE)
Number of subjects: 17
Study 21856809 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (2-g loading dose followed by 500 mg every 12 hours)
Number of subjects: 24
Study 21856809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 19707219 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet rich in virgin olive oil
Number of subjects: 187
Study 19707219 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet rich in nuts
Number of subjects: 187
Study 19707219 — intervention group
Group type: COMPARATOR
Intervention: Conventional low‐fat diet (control)
Number of subjects: 187
Study 17548664 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine transdermal patch
Number of subjects: 1000
Study 17548664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study 15114031 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin therapy (RPL-IVIg); 500 mg IVIg/kg/month
Number of subjects: 15
Study 15114031 — intervention group
Group type: COMPARATOR
Intervention: Multivitamin (placebo)
Number of subjects: 15
Study 15114031 — intervention group
Group type: COMPARATOR
Intervention: Normal pregnant women without APS
Number of subjects: 15
Study 15771407 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticoamygdalohippocampectomy
Number of subjects: 100
Study 9643400 — intervention group
Group type: EXPERIMENTAL
Intervention: Labour group (73 patients)
Number of subjects: 118
Study 9643400 — intervention group
Group type: COMPARATOR
Intervention: Elective caesarean section group (45 patients)
Number of subjects: 118
Study 7911416 — intervention group
Group type: EXPERIMENTAL
Intervention: Litmus paper
Number of subjects: 0
Study 7911416 — intervention group
Group type: COMPARATOR
Intervention: Intragastric pH probes
Number of subjects: 0
Study 2510255 — intervention group
Group type: EXPERIMENTAL
Intervention: Rioprostil 600 micrograms
Number of subjects: 9
Study 2510255 — intervention group
Group type: EXPERIMENTAL
Intervention: Rioprostil 300 micrograms
Number of subjects: 9
Study 2510255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 4940157 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy (B.C.G.)
Number of subjects: 191
Study 4940157 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent methotrexate
Number of subjects: 191
Study 4940157 — intervention group
Group type: COMPARATOR
Intervention: No further treatment
Number of subjects: 191
Study 31332110 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-pass technique for lenticule preparation
Number of subjects: 20
Study 31332110 — intervention group
Group type: COMPARATOR
Intervention: Double-pass technique for lenticule preparation
Number of subjects: 20
Study 28445471 — intervention group
Group type: EXPERIMENTAL
Intervention: Concise consent form
Number of subjects: 4229
Study 28445471 — intervention group
Group type: COMPARATOR
Intervention: Standard consent form
Number of subjects: 4229
Study 26102258 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicine Ball Training (MBT)
Number of subjects: 28
Study 26102258 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 28
Study 24444439 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg/day)
Number of subjects: 122
Study 24444439 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (20 mg/day)
Number of subjects: 122
Study 22967451 — intervention group
Group type: EXPERIMENTAL
Intervention: EC-T (epirubicin 90 mg/m², cyclophosphamide 600 mg/m² for 4 cycles, followed by docetaxel 80 mg/m² for 4 cycles)
Number of subjects: 95
Study 22967451 — intervention group
Group type: COMPARATOR
Intervention: TP (docetaxel 75 mg/m², carboplatin AUC = 5 for 6 cycles)
Number of subjects: 95
Study 22967451 — intervention group
Group type: EXPERIMENTAL
Intervention: EC-T
Number of subjects: 95
Study 22967451 — intervention group
Group type: COMPARATOR
Intervention: TP
Number of subjects: 95
Study 19645218 — intervention group
Group type: COMPARATOR
Intervention: LTG
Number of subjects: 38
Study 19645218 — intervention group
Group type: EXPERIMENTAL
Intervention: LTG + VPA
Number of subjects: 38
Study 17294378 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous full-time occlusion of the sound eye (24 hours per day)
Number of subjects: 53
Study 17294378 — intervention group
Group type: COMPARATOR
Intervention: Full-time occlusion of the sound eye 1 day more than the years of age, periodically alternating with occlusion of the amblyopic eye for 1 day
Number of subjects: 53
Study 16039494 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical pilocarpine 4%
Number of subjects: 14
Study 16039494 — intervention group
Group type: COMPARATOR
Intervention: Balanced salt solution (control)
Number of subjects: 14
Study 12460124 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis Youth Treatment (CYT) study
Number of subjects: 0
Study 12460124 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana Treatment Project (MTP)
Number of subjects: 0
Study 9877359 — intervention group
Group type: EXPERIMENTAL
Intervention: Td vaccine in Grade 6 students
Number of subjects: 410
Study 9877359 — intervention group
Group type: COMPARATOR
Intervention: Td vaccine in Grade 9 students
Number of subjects: 410
Study 7795925 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (4 mg orally)
Number of subjects: 0
Study 7795925 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 2612430 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A - standard brief description of upper G-I endoscopy
Number of subjects: 243
Study 2612430 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B - detailed description by the endoscopist
Number of subjects: 243
Study 2612430 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C - comprehensive explanation with pictures
Number of subjects: 243
Study 2612430 — intervention group
Group type: EXPERIMENTAL
Intervention: Group D - specially prepared video film of the procedure
Number of subjects: 243
Study 2612430 — intervention group
Group type: COMPARATOR
Intervention: Group E - patients who had previously undergone upper gastrointestinal endoscopy
Number of subjects: 243
Study 359245 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg diflunisal twice daily
Number of subjects: 90
Study 359245 — intervention group
Group type: COMPARATOR
Intervention: 25 mg codeine phosphate 4-times daily
Number of subjects: 90
Study 359245 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 31954884 — intervention group
Group type: EXPERIMENTAL
Intervention: ERAS protocol
Number of subjects: 94
Study 31954884 — intervention group
Group type: COMPARATOR
Intervention: Conventional perioperative care (control group)
Number of subjects: 94
Study 30100316 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryostretching
Number of subjects: 37
Study 30100316 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 37
Study 26386383 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic repair of OSB using a biocellulose patch
Number of subjects: 10
Study 26386383 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic repair of OSB
Number of subjects: 10
Study 24968955 — intervention group
Group type: COMPARATOR
Intervention: COT1 (45 hours of conventional occupational therapy)
Number of subjects: 0
Study 24968955 — intervention group
Group type: COMPARATOR
Intervention: COT2 (80 hours of conventional occupational therapy)
Number of subjects: 0
Study 24968955 — intervention group
Group type: EXPERIMENTAL
Intervention: FES + COT (40 hours of COT therapy + 40 hours of FES therapy)
Number of subjects: 0
Study 23156041 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxen (antioxidant)
Number of subjects: 391
Study 23156041 — intervention group
Group type: COMPARATOR
Intervention: Routine therapy (Control)
Number of subjects: 391
Study 20510800 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat back (RB) method
Number of subjects: 575
Study 20510800 — intervention group
Group type: COMPARATOR
Intervention: Standard (STD) iMedConsent
Number of subjects: 575
Study 18978404 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical disc arthroplasty
Number of subjects: 199
Study 18978404 — intervention group
Group type: COMPARATOR
Intervention: Arthrodesis
Number of subjects: 199
Study 18978404 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical disc arthroplasty and arthrodesis
Number of subjects: 199
Study 16102611 — intervention group
Group type: EXPERIMENTAL
Intervention: Open Repair (OR)
Number of subjects: 30
Study 16102611 — intervention group
Group type: COMPARATOR
Intervention: Endovascular Therapy (ET)
Number of subjects: 30
Study 11957554 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily regimen (2HRZ/2HR) - 2 months of isoniazid (H), rifampicin (R) and pyrazinamide (Z), followed by 2 months of H and R
Number of subjects: 314
Study 11957554 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined regimen (2HRZ/2H3R3) - 2 months of HRZ, followed by H and R given 3 times weekly for 2 months or 4 months if initial sputum specimens were culture positive
Number of subjects: 314
Study 10617009 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump surgery
Number of subjects: 200
Study 10617009 — intervention group
Group type: COMPARATOR
Intervention: Conventional on-pump surgery
Number of subjects: 200
Study 8951267 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS/NP team
Number of subjects: 821
Study 8951267 — intervention group
Group type: COMPARATOR
Intervention: Pediatric resident team
Number of subjects: 821
Study 1957749 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 1444
Study 7137874 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional metoprolol 100 mg twelve hourly
Number of subjects: 10
Study 7137874 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol S.A. (slow release formulation) once daily
Number of subjects: 10
Study 7137874 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol S.R. (slow release formulation) once daily
Number of subjects: 10
Study 7137874 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol S.A.
Number of subjects: 10
Study 7137874 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol S.R.
Number of subjects: 10
Study 7137874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31182369 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled eluforsen (up to 50 mg, dosed 3 times per week for 4 weeks)
Number of subjects: 0
Study 31182369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31852085 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-exposure prophylaxis (PrEP) adherence
Number of subjects: 392
Study 31852085 — intervention group
Group type: EXPERIMENTAL
Intervention: African American
Number of subjects: 392
Study 31852085 — intervention group
Group type: EXPERIMENTAL
Intervention: Incident chlamydia
Number of subjects: 392
Study 31852085 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiving items for sex
Number of subjects: 392
Study 27367473 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based education (CBE) program at home
Number of subjects: 246
Study 27367473 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard teaching)
Number of subjects: 246
Study 24326480 — intervention group
Group type: EXPERIMENTAL
Intervention: Lecture-based CPE
Number of subjects: 120
Study 24326480 — intervention group
Group type: EXPERIMENTAL
Intervention: Workshop-based CPE
Number of subjects: 120
Study 24326480 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 120
Study 24438599 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1.0 μg/kg intravenously for 10 minutes, maintained with 0.4 μg/kg and modulated from 0.2 to 0.7 μg/kg/hour in ICU
Number of subjects: 66
Study 24438599 — intervention group
Group type: COMPARATOR
Intervention: Propofol 0.1 mg/kg intravenously for 10 minutes, maintained with 1 to 2 mg/kg/hour in recovery room and ICU
Number of subjects: 66
Study 23062388 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen immunotherapy with higher serum level of 25(OH)D
Number of subjects: 36
Study 23062388 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen immunotherapy with 25(OH)D serum level higher than 30 ng/mL
Number of subjects: 36
Study 23062388 — intervention group
Group type: COMPARATOR
Intervention: Allergen immunotherapy
Number of subjects: 36
Study 19442372 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided fine-needle aspiration cytology (USFNAC)
Number of subjects: 112
Study 19442372 — intervention group
Group type: COMPARATOR
Intervention: Conventional palpation-guided fine-needle aspiration cytology (PFNAC)
Number of subjects: 112
Study 19442372 — intervention group
Group type: EXPERIMENTAL
Intervention: USFNAC
Number of subjects: 112
Study 19442372 — intervention group
Group type: COMPARATOR
Intervention: PFNAC
Number of subjects: 112
Study 17635283 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion group (pantoprazole 80 mg i.v. bolus followed by continuous infusion of 8 mg/h for 3 days)
Number of subjects: 168
Study 17635283 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus group (pantoprazole 80 mg i.v. bolus followed by 40 mg i.v. bolus every 12 h for 3 days)
Number of subjects: 168
Study 17635283 — intervention group
Group type: COMPARATOR
Intervention: No-treatment group (no acid suppression in the first 3 days)
Number of subjects: 168
Study 17635283 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion group vs Bolus group
Number of subjects: 168
Study 15138759 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion (300 mg)
Number of subjects: 71
Study 15138759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 11266685 — intervention group
Group type: COMPARATOR
Intervention: Magnetisation transfer ratio (MTR) histogram analysis in primary progressive MS patients
Number of subjects: 122
Study 11266685 — intervention group
Group type: COMPARATOR
Intervention: Magnetisation transfer ratio (MTR) histogram analysis in disabled relapsing onset patients
Number of subjects: 122
Study 11266685 — intervention group
Group type: EXPERIMENTAL
Intervention: Principal component (PC) analysis of MTR histogram
Number of subjects: 122
Study 11266685 — intervention group
Group type: COMPARATOR
Intervention: Magnetisation transfer ratio (MTR) histogram analysis in benign and nondisabled relapsing onset patients
Number of subjects: 122
Study 9885014 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal pregnancy cycles
Number of subjects: 0
Study 9885014 — intervention group
Group type: EXPERIMENTAL
Intervention: EPL cycles
Number of subjects: 0
Study 9885014 — intervention group
Group type: EXPERIMENTAL
Intervention: Early normal pregnancy
Number of subjects: 0
Study 9885014 — intervention group
Group type: COMPARATOR
Intervention: EPL
Number of subjects: 0